Cargando…

Expression of NF2 Modulates the Progression of BRAF(V600E) Mutated Thyroid Cancer Cells

BACKGROUND: We previously reported the frequent neurofibromatosis 2 (NF2) gene mutations in anaplastic thyroid cancers in association with the BRAF(V600E) mutation. We aimed to investigate the role of NF2 in thyroid cancer with BRAF mutation. METHODS: To identify the function of NF2 in thyroid cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Mi-Hyeon, Jeon, Min Ji, Kim, Tae Yong, Kim, Won Bae, Shong, Young Kee, Kim, Won Gu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599905/ https://www.ncbi.nlm.nih.gov/pubmed/31257748 http://dx.doi.org/10.3803/EnM.2019.34.2.203

Ejemplares similares

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAF(V600E)-Mutant Advanced Papillary Thyroid Carcinoma
por: Song, Eyun, et al.
Publicado: (2021)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Induction of the BRAF(V600E) Mutation in Thyroid Cells Leads to Frequent Hypermethylation
por: Yi, Jin Wook, et al.
Publicado: (2022)

Mitofusin-2 modulates the epithelial to mesenchymal transition in thyroid cancer progression
por: You, Mi-Hyeon, et al.
Publicado: (2021)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
por: Park, Charny, et al.
Publicado: (2015)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

Artificial intelligence to predict the BRAF(V600E) mutation in patients with thyroid cancer
por: Yoon, Jiyoung, et al.
Publicado: (2020)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
por: Jeon, Min Ji, et al.
Publicado: (2016)

Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer
por: Kim, Won Bae, et al.
Publicado: (2020)

The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades
por: Hong, A Ram, et al.
Publicado: (2014)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry
por: Swan, Kristine Zøylner, et al.
Publicado: (2022)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
por: Jeon, Min Ji, et al.
Publicado: (2021)

Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
por: Jeon, Min Ji, et al.
Publicado: (2022)

Graves’ disease diagnosed in remnant thyroid after lobectomy for thyroid cancer
por: Jin, Meihua, et al.
Publicado: (2022)

A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation
por: Kim, Wook Youn, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Current Status and Future Perspectives in Differentiated Thyroid Cancer
por: Kim, Tae Yong, et al.
Publicado: (2014)

BRAF(V600E) Mutation Enhances Estrogen-Induced Metastatic Potential of Thyroid Cancer by Regulating the Expression of Estrogen Receptors
por: Kim, Minjun, et al.
Publicado: (2022)

BRAF V600E and MAP2K1 Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma Cases
por: Shin, Sang-Yong, et al.
Publicado: (2015)

Proper Indication of BRAF(V600E) Mutation Testing in Fine-Needle Aspirates of Thyroid Nodules
por: Koh, Jieun, et al.
Publicado: (2013)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules
por: Rowe, Leslie R, et al.
Publicado: (2006)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
por: Robbins, Richard J., et al.
Publicado: (2020)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

BRAF V600E and Novel Somatic Mutations in Thyroid Cancer of Libyan Patients
por: Tounsi-Guettiti, Haifa, et al.
Publicado: (2022)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
por: Lee, Seong Jin, et al.
Publicado: (2011)

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
por: Paek, Se Hyun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a4ph8grhmhkmva258blt5vgpof